Researchers from University of Athens and National Centre For Scientific Research “Demokritos” have reported preclinical data from a study that aimed to assess the novel cryptochrome-2 (CRY2) stabilizer TH-301 in models of pancreatic ductal adenocarcinoma (PDAC). It was seen that treatment with TH-301 led to significant dose-, time- and cell type-dependent decreases in viability.